Generative AI adoption, regulatory scrutiny, DEI policy shifts, real-world evidence, and rare disease economics emerged as key themes across these most-read Applied Clinical Trials articles shaping ...
Phase III OASIS 4 trial showed 16.6% mean weight loss with oral semaglutide, outperforming placebo. The FDA approval of oral semaglutide marks the first GLP-1 pill for chronic weight management, ...
Review the performance, engagement, and satisfaction metrics sponsors and CROs should track to determine whether operational ...
If we can use AI or AI agents to automate those workflows, you can still run the same process, particularly as it relates to ...
In today’s ACT Brief, we examine why fragmented data systems continue to slow life sciences research, review how sponsor ...
Lunsumio VELO, a CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two or more systemic therapies. The GO29781 trial showed a 75% objective response rate ...
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...
Learn how clinical operations leaders can build technology adoption, transform workflows, and cultivate digitally savvy ...
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...
In today’s ACT Brief, we examine how sponsors are reassessing new engagement technologies to avoid increasing site burden, ...
Explore how expanding clinical trials into community and nontraditional sites, simplifying protocols, and leveraging AI can ...
Examine how evolving sourcing strategies, functional standardization, and system choices can help sponsors support sites more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback